Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Novo Nordisk Research Centre Oxford (NNRCO) was launched in 2017 as a strategic alliance between Oxford University, a global leader in metabolism research, and Novo Nordisk, the leading diabetes therapeutics company.

Novo Nordisk logo

 

 

about novo nordisk

Novo Nordisk is the world’s leading diabetes therapeutics company, with 95 years’ experience of innovation in diabetes care. The company has a longstanding relationship with the University of Oxford, itself a global leader in metabolism research, and in 2017 the Novo Nordisk Research Centre Oxford (NNRCO) was launched as a strategic alliance between the two organisations. 

ABOUT THE ALLIANCE AND NOVO NORDISK RESEARCH CENTRE OXFORD

The alliance between Novo Nordisk and Oxford aims to establish landmark collaborations for the advancement of the type 2 diabetes research, and to work towards innovative medicines that that make a difference in the lives of patients with diabetes. The scientific mission of NNRCO is to conduct world-class discovery research to identify new therapeutic targets in type 2 diabetes and its co-morbidities.

The NNRCO is an innovative academic-industry hybrid institute, with a focus on discovery research in the pre-competitive space. Collaborative co-creation projects are co-funded via the Strategic Alliance Committee, and NNRCO also participates in the training of the next generation of type 2 diabetes research scientists by co-sponsoring students. Find out more about funding from Novo Nordisk. 

 

Innovation Building ORC

 

Uniquely, the alliance has seen Novo Nordisk establish a presence onsite at the University of Oxford, with NNRCO employing up to 100 researchers between 2017 and 2021 who will be visitors to the University in various capacities. These NNRCO researchers will work in new state-of-the-art laboratories in the Innovation Building on Old Road Campus, which officially opened on the 12th September 2018. 

NNRCO itself is led by interim head Professor Allan Ertmann Karlsen and is composed of four departments - Explore NNRCO Departments. 

support for the alliance

The alliance is governed by a Joint Steering Committee, made up of parties from both Oxford University and Novo Nordisk. This joint governance structure allows for an alignment of research interests and offers an opportunity to work truly collaboratively. A collaboration committee has also been appointed that can act more swiftly to smaller collaborative opportunities.

The alliance benefits from a dedicated alliance manager, Dr Siobhan Dennis, who acts as a point of contact for both organisations and provides support for calls and projects. Please note that Dr Dennis is only able to advise University of Oxford staff on collaboration and roles with Novo Nordisk, and is not able to comment on speculative applications.

NNOSAC2018v2

Novo Nordisk Oxford Strategic Alliance (NNOSA) committee members & support: Front left to right -  Prof Hugh Watkins, Dr Lars Fogh Iversen, Dr Siobhan Dennis, Prof Mads Krogsgaard Thomsen, Prof Cecilia Lindgren and Dr Dorthe Lundsgaard.  Back left to right - Prof Allan Karlsen, Prof Marcus Schindler, Prof Mark McCarthy, Prof Jacob Sten Petersen and Prof Sir John Bell. Photo credit - John Carins

FURTHER INFORMATION

Page updated 25/08/2018